© Drägerwerk AG & Co. KGaA, 2020
Drägerwerk AG&Co.KGaACapital Markets Presentation
March 2020, Lübeck
© Drägerwerk AG & Co. KGaA, 2020
Disclaimer
2
Interim financial reports as well as preliminaries are not audited.
This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have been made to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entail risks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation.
This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation.
© Drägerwerk AG & Co. KGaA, 2020 3
Outlook
DrägerThe Company
Financials
© Drägerwerk AG & Co. KGaA, 2020 4
protectDräger products
supportsave
lives,
and
© Drägerwerk AG & Co. KGaA, 2020
Net sales developmentStrong growth independent of the global economy
5
Source: International Monetary Fund, World Economic Outlook Database
Net sales developmentDräger net sales in EUR million
Global gross domestic product
Stock-market crash
GulfWar
Mexican pesocrisis
Russianfinancial
crisis
Stock-marketcrash
IraqWar
Financialcrisis
Debtcrisis
2,500
2,000
1,500
1,000
500
0
3,000
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
© Drägerwerk AG & Co. KGaA, 2020
Dräger worldwideNet sales, sites and employees
6
55%
25%
20%
Africa, Asia, AustraliaEurope
Americas
Net Sales: EUR
~2.8 billionin 2019
70%
16%
14%
14,845employees
in 2019
Dräger-Sites21%
11%
10%
58%
Sales & Service Production, Quality,Logistics, Purchasing
R&D Administration
Production sites inEurope, America, Africa and Asia
Sales and Service organizations worldwide
Safety~35 %
Medical~65 %
© Drägerwerk AG & Co. KGaA, 2020
MarketsOur Customers
7
Fire services Oil and gas industry
Mining Chemical industry
Hospital
Other markets
© Drägerwerk AG & Co. KGaA, 2020
Medical division
8
Infinity Acute Care System
Clincal software solutions
Telemetry and IT-solutions
Medical supply units
Medical Gas supply systems
Medical lights and video solutions
Consumables and accessories
Classical-, Multivendor product service, Professional Service
Training
Anaesthesiology
Ventilation
Thermoregulation
Patient Monitoring & Clinical IT
Workplace Infrastructure
Hospital Consumables & Service
Intensive Care Operating Room Neonatal CareHospital wide
Solutions
Note: Market position based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.
Anaesthesia workstations and vaporizers
#1 in Europe and #2 in the US market
Emergency & Transport-, Neonatal- and Intensive Care ventilators
Respiratory monitoring
#1 in Europe
Incubators and Warming Therapy
#2 worldwide and #1 in Europe
© Drägerwerk AG & Co. KGaA, 2020
Safety division
9
Breathing Systems
Gas Detection Systems
Personal Protection Equipment
Impairment Check Equipment
Engineered Solutions
Service
Fixed and mobile gas detection systems
#1 worldwide and #1 in Europe
Alcohol- and drug screeningdevices
Interlock devices
#1 worldwide and #1 in Europe
Protection equipment for hazardous working environments
Body and Head protection, rescue and escape devices, Masks and Filters, etc.
Self-contained BreathingAppartus for fire fighters
#2 worldwide and #1 in Europe
Customer specific solutions
mobile and stationary firefighting training systems
Rescue chambers
Spareparts and consumables
Product Service
Rental, On-site shops and Shutdown Service
Marine-Offshore Service
Note: Market positions based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.
Fire Service
Oil & Gas Chemical Mining Other Markets
© Drägerwerk AG & Co. KGaA, 2020
Medical and safety technology providing long-term growth prospects
10
Hospital
Attractive growth prospects in sizeable markets …
… in developed markets…
… as well as in emerging markets
Oil&Gas Chemical Mining FireService
Average expected annual market growth for the global medical equipment market significantly exceeding growth in many other sectors
Strong growth prospects in both developed and emerging markets
Very diversified markets with numerous product and service offerings
Attractive growth prospects for target sectors (e.g. industry) and growing safety investments
Rapidly aging population and consequently increasing healthcare expenditure
Increasing demand for medical equipment to improve clinical workflows and efficiency
Increasingly stricter safety regulations
Rising environmental awareness
Improved outlook for target markets
Strong growth of GDP and population resulting in a demand for improved medical services
Political benefits from investments in health care sector
Increasingly higher safety standards
Increasing industrial hygiene awareness
Strong growth of key customer sectors
© Drägerwerk AG & Co. KGaA, 2020
Strategy for profitable growth
11
Management of innovation rate through continuous improvements in quality and R&D processes
Expansion of market positions in attractive markets. Special focus on profitable growth in developing countries
Expansion of service and consumables business
Investments for future growth
1
2
3
4
© Drägerwerk AG & Co. KGaA, 2020
Technology and innovation leadership to drive profitable growth
12
Strong R&D focus Innovation to enhance future growth (examples)
Approximately 1,300 employees in R&D around the globe.
EUR ~270 million spent for R&D activities in 2019.*
Certified test-center at Lübeck headquartersupports innovation- and approval process.
Qualitymanagement organization with >100 employees.
Very close collaboration with customers to develop new and improve existing products.
Technological competency and high quality standards result in leading market positions and high barriers to entry.
Babyleo ®
Incuwarmer: combination of a
classical incubator and warming bed functionalities.
Dräger X-am® 8000
Multigas detector for measurement of up to 7 gases simultaneously.
* no meaningful capitalization of R&D budget
Atlan®
New anesthesia family with network
connectivity supporting SDC and new user
interface
© Drägerwerk AG & Co. KGaA, 2020
Exploit growth potentials in developing countries
13
Investments in profitable growth
in developing countries
2
Focus on the specific needs of customer in developing countries
Identify growth potential in strong growing markets like China, Brazil and India
Capitalize on the significant investments into the Sales & Service infrastructure and specific
market knowledge, especially in our Region AAA and in Central- and South-America
Enhance engagement with partners in developing countries to expand local presence with R&D,
manufacturing, sales and after sales business
Net sales
Developed Markets76 %
Newly industrialized countries
24 %
Focused product range
Fabius Plus XLVista 120Savina Color
© Drägerwerk AG & Co. KGaA, 2020
Service- and consumables business a clear focus of our Sales activities
14
Further expansion of service and consumables
business3
Dräger Services Dräger Consumables
Functionalities with added value, e.g. optimizing workflow with RFID-based communication between consumables part and therapy machine
Dräger quality to improve hygienic standards
Dräger value add especially in development of consumables. Production usually via suppliers
Partly proprietary consumable products, e.g. Dräger-Tubes
Globally over 3,000 service technicians
Fast and reliable service (repairs and spare parts) is a critical factor for customers
Dräger Service technicians important for customer loyalty
Efficient service solutions via remote service
Broad offerings of product service
New services in the areas of Rental, Multi-Vendor and Marine-offshore
Capitalize on large installed base to expand after sales business
Focus on combined sale of equipment and after sales contracts
Expansion of disposable consumables business
© Drägerwerk AG & Co. KGaA, 2020
Investments will support future growth…
15
WE ARE INVESTING: WE ARE RESTRUCTURING:
Sales resources
&-capabilities
R&Droadmap
Strengthening Safety sales channels
FGDS System Centers
Key Account Management
Digital distribution channels
Global roll out of Future Technician Workplace
More R&D resources (focus on SW-development)
Partnership with external development partners
Accelerate EM product portfolio
New organizational set-up and business steering according to Medical and Safety:
Introduction of business units with full product and customer accountability.
Business units are combined within a Medical division and a Safety division, each managed by a dedicated board member.
Financial reporting according to the new divisional structure Medical and Safety. (as of FY 2020)
One dedicated board member responsible for the global sales organization.
© Drägerwerk AG & Co. KGaA, 2020 16
Financials
© Drägerwerk AG & Co. KGaA, 2020
Business developmentDräger Group 5y view
17
Note: restructuring charges included in FY EBIT: EUR 35 million in 2015, EUR 10 million in 2016Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital
Net Sales% growth% growth (FX adjusted)
Gross margin
Functional Expenses% of Net Sales
EBITEBIT Margin
DVA -32.7
-1,116.8 -40.2%
66.6 2.4%
2019
€ million
2,780.8 7.2%5.9%
42.7%
70.7
-992.0 -38.6%
155.7 6.1%
2017
€ million
2,572.3 1.9%3.3%
44.8%
2015
€ million
2,608.9 7.2%2.9%
-1,098.4 -42.1%
-999.2 -39.6%
136.9 5.4%
66.7 2.6%
2016
€ million
2,523.8 -3.3%-1.5%
45.0%44.9%
49.8 -46.3
2018
€ million
2,595.0 0.9%3.9%
42.7%
-1,042.2 -40.2%
62.6 2.4%
-26.5
© Drägerwerk AG & Co. KGaA, 2020
Key figuresDräger Group 5y view
18Note: Investments 2015 include EUR ~60m for M&A
Change
%
Cashflow (from operating activities) >+100
Investments 1.4
Cash and cash equivalents1 9.3
Net financial debt1 >+100
Net financial debt 1 /EBITDA 2
Capital employed 1 4.5 ROCE (EBIT 2 /Capital employed 1)
Net Working Capital1 -3.4
Equity ratio -3.0pp
1 Values as of reporting date2 EBITDA and accordingly EBIT of the last twelve months
196.3
88.7 0.50
1,401.3 4.8%
662.7
41.9
2019
€ million
164.4
78.8
247.6
-29.2 -0.12
1,243.6 12.5%
557.2
45.4
2017
€ million
143.3
106.2
39.9
196.9
172.8
145.3 0.96
34.7 0.16
1,247.0 11.0%
563.2
43.4
€ million
195.3
99.9
221.5
2016
1,269.3 5.3%
582.3
40.9
2015
€ million
2018
€ million
4.1
77.8
179.6
43.3 0.29
1,341.3 4.7%
644.6
44.8
© Drägerwerk AG & Co. KGaA, 2020 19
Outlook
© Drägerwerk AG & Co. KGaA, 2020
Outlook
20
2019 guidance 2019 2020 guidance
Net sales+4.0 - +6.0 %
(net of currency effects)
+5.9 %(net of currency
effects)
+1.0 - +4.0 %(net of currency
effects)
EBIT margin 1.0 - 3.0 % 2.4 % 1.0 – 4.0 %
© Drägerwerk AG & Co. KGaA, 2020
Guidance 2020
22
2019 2020e
Net sales5.9%
(net of currency effects)+1.0 - +4.0 %
(net of currency effects)
EBIT margin 2.4% 1.0 - 4.0 %1
Dräger Value Added EUR -32.7 millionin the range
EUR -70 to +20 million
Other forecast figures:
Gross margin 42.7 %on prior year's level
(+ / - 1pp)
R&D expenses EUR 263.7 million EUR 275 - 290 million
Interest result EUR -17.0 million on prior year's level
Days working capital (DWC)2 109.4 days stable
Investment volume3 EUR 78.8 million EUR 80 - 95 million
Net financial debt EUR 88.7 million improvement
1 Based on exchange rates at the start of fiscal year 20202The calculation method for this figure has been adjusted at the end of fiscal year 2019. The figure shown here for 2019 is based on the modified method.3Excluding acquisitions and the effects of capitalizing right-of-use assets pursuant to IFRS 16
© Drägerwerk AG & Co. KGaA, 2020
Dräger management
23
At Dräger since 2015
Chairman of the Executive Board CEO
At Dräger since 1992At Dräger since 2008
At Dräger since 2015
Stefan Dräger
Vice Chairman of the Executive BoardCFO
Gert-HartwigLescow
Board member medical division
Rainer Klug Dr. Reiner Piske
Board member Sales and HR
At Dräger since 2010
Board member safety division
Anton Schrofner
© Drägerwerk AG & Co. KGaA, 2020
Successors of Dr. Heinrich Dräger
Stefan Dräger GmbH
Dräger Foundation
Members of the Dräger family
Dr. Heinrich Dräger GmbH
Free float
Shareholder structure
24
ShareholdingCommon shares
67.2 %
28.8%
4.0%
10,160,000 common shares (28.8 % free float)7,600,000 preferred shares (100.0 % free float)
ShareholdingDr. Heinrich Dräger GmbH
58.7%
23.2%18.1%
© Drägerwerk AG & Co. KGaA, 2020
IFRS 16 impact
25
in € million
Increase / Improvement as of December 31,2019
EBITDA 46.8
EBIT 4.4
Cash flow from operating activities 42.4
Net financial debt 107.8
Investments 42.5
Capital employed 100.9
© Drägerwerk AG & Co. KGaA, 2020
Business development YTDDräger Group
26
© Drägerwerk AG & Co. KGaA, 2020
Key figuresDräger Group
27
Cashflow (from operating activities)
Investments
Cash and cash equivalents1
Net financial debt1
Net financial debt 1 /EBITDA 2
Capital employed 1
ROCE (EBIT 2 /Capital employed 1)
Net Working Capital1
Equity ratio
1 Values as of reporting date2 EBITDA and accordingly EBIT of the last twelve months
196.3
88.7 0.50
1,401.3 4.8%
662.7
41.9
2019
€ million
164.4
78.8
247.6
-29.2 -0.12
1,243.6 12.5%
557.2
45.4
2017
€ million
143.3
106.2
34.7 0.16
1,247.0 11.0%
563.2
43.4
€ million
195.3
99.9
221.5
2016 2018
€ million
4.1
77.8
179.6
43.3 0.29
1,341.3 4.7%
644.6
44.8
© Drägerwerk AG & Co. KGaA, 2020
Business developmentRegions 5 year view
28
2015 2016 2017 2018 2019
SEGMENT EUROPE
Order En tr y 1 € m illion 1,391.0 1,382.5 1,447.8 1,450.2 1,528.9
Net Sales 1 € m illion 1,420.7 1,384.3 1,415.5 1,431.9 1,503.3
EBIT € m illion 59.4 84.5 108.1 82.0 68.5
EBIT margin % 4.2 6.1 7.6 5.7 4.6
SEGMENT AMERICA
Orde r En tr y 1 € m illion 496.8 515.0 509.2 526.0 553.1
Ne t Sales 1 € m illion 509.1 503.7 510.4 499.3 547.7
EBIT € m illion -18.6 10.3 4.0 -30.2 -14.2
EBIT margin % -3.7 2.0 0.8 -6.0 -2.6
SEGMENT AFRICA, ASIA, AUSTRALIA
Orde r En tr y 1 € m illion 644.5 641.2 657.6 710.2 714.2
Ne t Sales 1 € m illion 679.1 635.8 646.4 663.8 729.8
EBIT € m illion 25.8 42.1 43.7 10.8 12.4
EBIT margin % 3.8 6.6 6.8 1.6 1.7
1 year 2014 were adjusted pro-forma due to the change in segment reporting.
© Drägerwerk AG & Co. KGaA, 2020
Business developmentRegions quarter
29
© Drägerwerk AG & Co. KGaA, 2020
Business developmentRegions YTD
30
Europe Americas Africa, Asia, Australia Dräger Group
12M 2018 12M 2019 12M 2018 12M 2019 12M 2018 12M 2019 12M 2018 12M 2019
€ million € million € million € million € million € million € million € million
Order entry 1,450.2 1,528.9 526.0 553.1 710.2 714.2 2,686.5 2,796.1
Net Sales 1,431.9 1,503.3 499.3 547.7 663.8 729.8 2,595.0 2,780.8
EBITDA 123.6 133.3 -8.2 14.2 32.6 46.3 148.0 193.8
EBIT 82.0 68.5 -30.2 -14.2 10.8 12.4 62.6 66.6
EBIT-margin 5.7 4.6 -6.0 -2.6 1.6 1.7 2.4 2.4
Capital Employed1 592.0 642.0 337.5 327.2 411.7 432.2 1,341.3 1,401.3
ROCE1,2 13.9 10.7 -8.9 -4.3 2.6 2.9 4.7 4.8
DVA 41.4 23.1 -51.6 -37.5 -16.3 -18.4 -26.5 -32.7 1 Values at due date2 EBIT of the last twelve months
© Drägerwerk AG & Co. KGaA, 2020
Business developmentMedical and Safety 5 year view
31
2015 2016 2017 2018 2019
Medical
Orde r En tr y € m illion 1,646.0 1,662.6 1,683.7 1,723.4 1,728.6
Net Sales € m illion 1,698.8 1,647.4 1,668.0 1,643.0 1,741.8
EBIT € m illion 46.2 85.3 92.9 6.9 13.1
EBIT margin % 2.7 5.2 5.6 0.4 0.8
Safe ty
Orde r En tr y € m illion 886.2 876.1 931.0 963.1 1,067.6
Net Sales € m illion 910.1 876.5 904.3 952.0 1,039.1
EBIT € m illion 20.5 51.6 62.8 55.8 53.5
EBIT margin % 2.2 5.9 6.9 5.9 5.1
© Drägerwerk AG & Co. KGaA, 2020
Business developmentMedical 2019
32
Q4 2018 Q4 2019 12M 2018 12M 2019
€ million € million € million € million
Order entry 480.5 483.9 0.7 -0.3 1,723.4 1,728.6 0.3 -1.2
Europe 233.5 246.0 5.3 4.8 852.6 871.2 2.2 2.1
America 112.3 113.8 1.3 1.0 361.4 370.3 2.5 -1.0
Africa, Asia, Australia 134.7 124.1 -7.8 -10.2 509.3 487.0 -4.4 -6.8
Net Sales 562.8 572.9 1.8 0.8 1,643.0 1,741.8 6.0 4.6
Europe 261.7 281.1 7.4 7.0 833.5 868.9 4.2 4.3
America 130.9 119.3 -8.9 -8.8 343.6 370.9 7.9 4.6
Africa, Asia, Australia 170.2 172.5 1.4 -1.1 465.8 502.0 7.8 5.1
EBIT 63.0 45.8 -27.3 6.9 13.1 90.8
EBIT-margin (%) 11.2 8.0 0.4 0.8
Change
% (FX adj.)
Change
% %
Change
% (FX adj.)
Change
© Drägerwerk AG & Co. KGaA, 2020
Business developmentSafety 2019
33
Q4 2018 Q4 2019 12M 2018 12M 2019
€ million € million € million € million
Order entry 274.7 296.1 7.8 7.4 963.1 1,067.6 10.9 10.0
Europe 168.1 186.2 10.7 10.6 597.5 657.7 10.1 10.3
America 50.6 50.7 0.2 0.3 164.6 182.8 11.0 7.0
Africa, Asia, Australia 56.0 59.3 5.8 3.9 200.9 227.2 13.1 11.6
Net Sales 303.2 309.1 2.0 2.0 952.0 1,039.1 9.1 8.4
Europe 186.2 194.8 4.6 4.6 598.4 634.5 6.0 6.3
America 50.7 47.2 -6.8 -4.6 155.6 176.9 13.6 10.1
Africa, Asia, Australia 66.3 67.1 1.2 -0.2 198.0 227.7 15.0 13.6
EBIT 40.6 23.7 -41.8 55.8 53.5 -4.1
EBIT-margin (%) 13.4 7.7 5.9 5.1
Change
% (FX adj.)
Change
%
Change Change
% % (FX adj.)
© Drägerwerk AG & Co. KGaA, 2020
Functional expenses5 year view
34
© Drägerwerk AG & Co. KGaA, 2020
Functional expensesYTD 2019
35
R&D% of Net Sales
Sales & Marketing% of Net Sales
Administration% of Net Sales
SG&A% of Net Sales
Functional Expenses total% of Net Sales
Headcount1
1 Values as of reporting date
-22.4%
-219.4 -7.9%
-841.3 -30.3%
-1,116.8 -40.2%
14,845
2019
€ million
-263.7 -9.5%
-621.9 -22.0%
-197.7 -7.7%
-764.0 -29.7%
-992.0 -38.6%
13,739
2017
€ million
-234.7 -9.1%
-566.3
13,263
-762.1 -30.2%
-39.6%-999.2
2016
€ million
-219.0 -8.7%
-554.7 -22.0%
-207.4 -8.2%
2018
€ million
-252.2 -9.7%
-592.6 -22.8%
-198.5 -7.6%
-791.1 -30.5%
-1,042.2 -40.2%
14,399
© Drägerwerk AG & Co. KGaA, 2020
Cash flow statement5 year view
36
Change
%
Group net profit 33.3 81.7 98.5 34.9 33.8 -3.2
Change in inventories -5.4 17.4 -30.0 -76.9 -24.5 68.1
Change in receivables -44.6 31.3 -22.4 -41.0 0.4 >+100
Change in payables -22.8 -10.2 22.2 -2.3 3.9 >+100
Depreciation and amortization 84.2 85.8 84.2 85.3 127.1 49.1
Other operating cash flow items -4.8 -10.6 -9.3 4.2 23.7 >+100
Operating cash flow 39.9 195.3 143.3 4.1 164.4 >+100
Investing cash flow -167.0 -77.3 -65.5 -63.5 -62.1 2.3
Free cash flow -127.1 118.1 77.8 -59.4 102.4 >+100
Financing cash flow -1.3 -70.0 -41.9 -6.2 -87.9 >-100
Change in cash1 -128.4 48.1 35.9 -65.6 14.5 >+100
Cash and cash equivalents2 172.8 221.5 247.6 179.6 196.3 9.3
1 Change in cash and cash equivalents, i.e. without any effect of exchange rates2 Values as of reporting date
2019
€ million
2017
€ million
2016
€ million
2015
€ million
2018
€ million
© Drägerwerk AG & Co. KGaA, 2020
Balance sheet
37
31 Dec 2018 31 Dec 2019 Change
€ million € million %
Intangible Assets 336.0 334.0 -0.6 Property, plant and equipment (incl. Right-of-use assets) 429.1 526.3 22.6 Other noncurrent assets 168.6 201.2 19.3 Noncurrent assets 933.7 1,061.4 13.7
Inventories 459.2 485.2 5.7 Trade receivables 703.9 710.7 1.0 Other current assets 133.9 117.3 -12.4
Cash and cash equivalents 179.6 196.3 9.3 Current assets 1,476.5 1,509.5 2.2
Total assets 2,410.2 2,570.9 6.7
© Drägerwerk AG & Co. KGaA, 2020
Balance sheet
38
31 Dec 2018 31 Dec 2019 Change
€ million € million %
Equity 1,080.7 1,076.4 -0.4
Liabilities from participation certificates 24.8 26.0 4.6
Provisions for pensions and similar obligation 339.3 390.9 15.2 Noncurrent interest bearing loans 125.1 118.6 -5.2 Other noncurrent liabilities 117.0 212.5 81.6
Noncurrent liabilities 606.2 748.0 23.4
Current Provisions 201.3 215.1 6.9 Current loans and liabilities to banks 90.1 51.0 -43.4 Trade payables 201.4 205.1 1.8
Other current liabilities 230.5 275.4 19.4 Current liabilities 723.3 746.6 3.2
Total equity and liabilities 2,410.2 2,570.9 6.7
© Drägerwerk AG & Co. KGaA, 2020
Earnings per share
39
+
=
PCs = participation certificates (Genussscheine)
2017 2018 2019Net profit (less the share of earnings attributable to non-controlling interests)
'000 € 98,530 34,355 33,350
Scenario: 100% pay-out ratio 100% 100% 100%
tax benefit from pay-out to PCs* '000 € 9,493 3,302 3,205
Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 108,023 37,657 36,555 100%
Earnings attributable to PCs** '000 € 34,420 11,973 11,621 32%
Earnings attributable to shares '000 € 73,603 25,685 24,934 68%
EPS (common share) € 4.12 1.42 1.38
EPS (preferred share) € 4.18 1.48 1.44
Scenario: actual/proposed pay-out ratio 11.6% 12.7% 13.0%
tax benefit from pay-out to PCs* '000 € 960 341 341
Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 99,490 34,696 33,691 100%
Earnings attributable to PCs** '000 € 3,482 1,236 1,236 4%
Earnings attributable to shares '000 € 96,008 33,460 32,455 96%
EPS (common share)*** € 5.38 1.86 1.80
EPS (preferred share)*** € 5.44 1.92 1.86* tax benefit arises from the tax deductible pay-out to the PCs; please refer to Annual Report 2019, note 19
** without minimum dividend (as interest, the mimimum dividend is already included in net earnings)
** the EPS is not calculated in accordance with IAS 33
© Drägerwerk AG & Co. KGaA, 2020
Innovation share
40
Share on new products and upgrades medical1
1 Launched in the last 3 years; products are regarded as new, if they enable Dräger to either enter a new market segment or if products are regarded as completely new according to Dräger‘s customers and Dräger‘s sales force. Upgrades are those products, which serve existing Dräger markets, but their functionality is perceived as significantly enhanced by Dräger‘s customers and Dräger‘s sales force.
New productsUpgrades
Net sales
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
20%
7%
2015
27%
25%
2019
5%
30%
22%
2014
10%
32%
18%
2%
2016
20%
21%
3%
2017
24%
23%
5%
2018
28%
© Drägerwerk AG & Co. KGaA, 2020
Financial calendar
41
March 5, 2020 - Final 2019 figuresConference call
April 30, 2020 - Report for the first three months 2020 Conference call
May 8, 2020 - Annual shareholders' meeting, Lübeck, Germany
August 13, 2020 - Report for the first six months 2020 Conference call
October 29, 2020 - Report for the first nine months 2020 Conference call
Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January.
© Drägerwerk AG & Co. KGaA, 2020
Contact
42
Melanie Kamann Thomas Fischler
Corporate Communications Investor Relations
Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaA
Moislinger Allee 53−55 Moislinger Allee 53−55
23558 Lübeck, Germany 23558 Lübeck, Germany
Tel +49 451 882-3998 Tel +49 451 882-2685
Fax +49 451 882-3944 Fax +49 451 882-3296
Mobile +49 170 8558152 Mobile +49 151 12245295
[email protected] [email protected]
www.draeger.com www.draeger.com